CANNDOC Pharma

Pharma-grade Cannabis Products

Health Tech & Life Sciences
Acquired by InterCure
Acquired Herzliya, Israel Founded 2008
Last updated 2026-06-18
Total raised
Stage
Acquired
Founded
2008
Headcount
7
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences

About

Canndoc is developing pharma-grade cannabis products. Over the years, Canndoc has provided more than 500,000 doses to 15,000 patients, demonstrating expertise across the value chain from research, cultivation, and processing to product development and good manufacturing practice (GMP) clinical trial pipeline initiation. Driven by the mission of meeting patients' needs and improving their quality of life, Canndoc's GMP-standard products are prescribed for a range of indications including neuropathic pain, pain from cancer, inflammatory bowel disease, post-traumatic stress disorder, Parkinson's disease, and epileptic seizures. Canndoc is a fully owned subsidiary of Israeli Medical Cannabis, Intercure. Its products and genetics cover European, Canadian, and Israeli regulatory requirements.

Q&A

What is CANNDOC Pharma's primary business?
CANNDOC Pharma develops pharma-grade cannabis products, focusing on research, cultivation, processing, and product development, with a GMP clinical trial pipeline.
When was CANNDOC Pharma founded?
CANNDOC Pharma was founded in January 2008.
Who acquired CANNDOC Pharma and when?
CANNDOC Pharma was acquired by InterCure in September 2018.
What is the employee count of CANNDOC Pharma?
CANNDOC Pharma has 1-10 employees.
What medical conditions do CANNDOC Pharma's products address?
CANNDOC Pharma's GMP-standard products are prescribed for conditions such as neuropathic pain, cancer pain, inflammatory bowel disease, post-traumatic stress disorder, Parkinson's disease, and epileptic seizures.
In which countries are CANNDOC Pharma's products and genetics regulated?
CANNDOC Pharma's products and genetics comply with regulatory requirements in Europe, Canada, and Israel.
Who is the CEO of CANNDOC Pharma?
Alexander Rabinovitch is the CEO of CANNDOC Pharma.
What is the primary sector of CANNDOC Pharma?
CANNDOC Pharma's primary sector is Health Tech & Life Sciences.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical Cannabis
Technologies
Materials & SubstancesRaw MaterialsBiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2GB2B

Highlights

1 Patents

Tags

cancertherapeuticsparkinsonepilepsygeneticspain-reliefoncologyinflammatory-diseasescannabismedical-cannabisoral-drugspharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitecanndoc.com/
LinkedInlinkedin.com/company/13028545

Identifiers & details

Founded2008-1
Employees (exact)7
Status reasonAcquired by InterCure on Sep 2018

Acquisitions & public offerings

Acquired by InterCure 2018-09

Radar intelligence

Web history (Wayback)

Domaincanndoc.com

Certificate / subdomain footprint

Subdomains2